Shigeki Seto

List of Publications by Year
in descending order

25	627	687363 13	677142 22
papers	citations	h-index	g-index

30	30	30	775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model. Bioorganic and Medicinal Chemistry, 2021, 34, 116015.	3.0	2
2	Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP 1 receptor antagonists. Bioorganic and Medicinal Chemistry, 2017, 25, 3406-3430.	3.0	4
3	Novel pyrazolo[1,5- a]pyridines as orally active EP 1 receptor antagonists: Synthesis, structure-activity relationship studies, and biological evaluation. Bioorganic and Medicinal Chemistry, 2017, 25, 2635-2642.	3.0	20
4	Discovery of novel pyrazolo[1,5-a]pyridine-based EP1 receptor antagonists by scaffold hopping: Design, synthesis, and structure-activity relationships. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4044-4050.	2.2	14
5	PBr3-mediated unexpected reductive deoxygenation of Î±-aryl-pyridinemethanols: synthesis of arylmethylpyridines. Tetrahedron, 2016, 72, 1566-1572.	1.9	6
6	Synthesis of 2-Arylpyrazolo[1,5-a]pyridines by Suzukiâ€“Miyaura Cross-Coupling Reaction. Synthesis, 2015, 47, 3221-3230.	2.3	8
7	Direct access to 2-aminopyrazolo[1,5-a]pyridines via N-amination/cyclization reactions of 2-pyridineacetonitriles. Tetrahedron Letters, 2014, 55, 5963-5966.	1.4	8
8	Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3Î² (GSK-3Î²) inhibitors for type 2 diabetics. Bioorganic and Medicinal Chemistry, 2012, 20, 1188-1200.	3.0	19
9	Synthesis and structureâ€“activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3Î². Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5948-5951.	2.2	18
10	Design, Synthesis, and Structureâ^'Activity Relationship Studies of Novel 2,4,6-Trisubstituted-5-pyrimidinecarboxylic Acids as Peroxisome Proliferator-Activated Receptor Î³ (PPARÎ³) Partial Agonists with Comparable Antidiabetic Efficacy to Rosiglitazone. Journal of Medicinal Chemistry, 2010, 53, 5012-5024.	6.4	18
11	Chemoselective Displacement of Methylsulfinyl Group with Amines to Provide 2-Alkylamino-4,6-disubstituted Pyrimidine-5-carboxylic Acid. Heterocycles, 2009, 78, 2263.	0.7	4
12	Total Synthesis of Vinblastine, Vincristine, Related Natural Products, and Key Structural Analogues. Journal of the American Chemical Society, 2009, 131, 4904-4916.	13.7	303
13	Analysis of crucial structural requirements of 2-substituted pyrimido[4,5-b][1,5]oxazocines as NK1 receptor antagonist by axially chiral derivatives. Bioorganic and Medicinal Chemistry, 2007, 15, 5083-5089.	3.0	14
14	Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists. Bioorganic and Medicinal Chemistry, 2005, 13, 5717-5732.	3.0	33
15	2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1485-1488.	2.2	23
16	Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1479-1484.	2.2	25
17	Convenient Synthesis of 7-Aryl-3,4,5,6-tetrahydro-2H-pyrido[4,5-b]- and [2,3-b]-1,5-oxazocine-6-ones.. ChemInform, 2005, 36, no.	0.0	0
18	Design and Synthesis of Novel 9-Substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 Antagonist.. ChemInform, 2005, 36, no.	0.0	0

#	Article	IF	Citations
19	2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b] [1,5]oxazocin-5-one as a Structurally New NK1 Antagonist.. ChemInform, 2005, 36, no.	0.0	0
20	Convenient synthesis of 7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,5-b]- and [2,3-b]-1,5-oxazocine-6-ones. Tetrahedron Letters, 2004, 45, 8475-8478.	1.4	19
21	Novel Seco Cyclopropa[c]pyrrolo[3,2-e]indole Bisalkylators Bearing a 3,3â€˜-Arylenebisacryloyl Group as a Linker. Journal of Medicinal Chemistry, 2001, 44, 1396-1406.	6.4	43
22	The novel cyclopropapyrroloindole(CPI) bisalkylators bearing 3,3â€²-(1,4-phenylene)diacryloyl group as a linker. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2003-2004.	2.2	18
23	A Straightforward Preparation of Chiral 5-(Aminomethyl)oxazole Derivatives from .ALPHA.-Amino Esters and .ALPHA.-Lithiated Isocyanides.. Chemical and Pharmaceutical Bulletin, 1998, 46, 860-862.	1.3	12
24	Quinolizidines. XXXIII. A Chiral Synthesis of (-)-Ophiorrhizine, a Pentacyclic Quaternary Indole Alkaloid from Ophiorrhiza major RIDL.. Chemical and Pharmaceutical Bulletin, 1995, 43, 49-52.	1.3	9
25	Absolute Stereochemistry of the Pentacyclic Quaternary Indole Alkaloid Ophiorrhizine: Synthetic Incorporation of Cincholoipon Ethyl Ester into (-)-Ophiorrhizine. Heterocycles, 1994, 38, 1741.	0.7	7